UBS Group
CYCN

UBS Group’s Cyclerion Therapeutics CYCN Stock Holding History

UBS Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Sell
3,135
-256
-8% -$831 ﹤0.01% 8543
2026
Q1 		$5.26K Buy
3,391
+3,015
+802% +$4.29K ﹤0.01% 8812
2025
Q4 		$478 Buy
376
+327
+667% +$584 ﹤0.01% 9942
2025
Q3 		$113 Sell
49
-9,678
-99% -$26.3K ﹤0.01% 9898
2025
Q2 		$28.3K Sell
9,727
-3,274
-25% -$9.78K ﹤0.01% 8206
2025
Q1 		$32.5K Buy
13,001
+3,334
+34% +$9.93K ﹤0.01% 7888
2024
Q4 		$31.1K Buy
9,667
+9,522
+6,567% +$26.5K ﹤0.01% 7576
2024
Q3 		$376 Sell
145
-2,561
-95% -$7.53K ﹤0.01% 8969
2024
Q2 		$6.22K Buy
2,706
+182
+7% +$517 ﹤0.01% 7938
2024
Q1 		$8.08K Buy
2,524
+296
+13% +$946 ﹤0.01% 7347
2023
Q4 		$7.46K Buy
2,228
+1,952
+707% +$5.64K ﹤0.01% 7624
2023
Q3 		$944 Buy
276
+90
+48% +$324 ﹤0.01% 8215
2023
Q2 		$766 Sell
186
-526
-74% -$2.73K ﹤0.01% 8111
2023
Q1 		$6.18K Sell
712
-199
-22% -$2.51K ﹤0.01% 7949
2022
Q4 		$12K Buy
+911
New +$10.8K ﹤0.01% 8322
2022
Q2 		– Sell
-182
Closed -$4K – 10405
2022
Q1 		$4K Buy
+182
New +$4.38K ﹤0.01% 9283
2021
Q4 		– Sell
-177
Closed -$11K – 10322
2021
Q3 		$11K Buy
177
+163
+1,164% +$10.7K ﹤0.01% 7872
2021
Q2 		$1K Sell
14
-220
-94% -$13.8K ﹤0.01% 9139
2021
Q1 		$13K Sell
234
-37
-14% -$2.78K ﹤0.01% 7729
2020
Q4 		$17K Buy
271
+251
+1,255% +$17.1K ﹤0.01% 7052
2020
Q3 		$2K Sell
20
-319
-94% -$36.5K ﹤0.01% 7646
2020
Q2 		$40K Sell
339
-369
-52% -$30.9K ﹤0.01% 6055
2020
Q1 		$38K Sell
708
-708
-50% -$50.5K ﹤0.01% 6038
2019
Q4 		$77K Sell
1,416
-531
-27% -$49.6K ﹤0.01% 6125
2019
Q3 		$471K Buy
1,947
+1,055
+118% +$228K ﹤0.01% 4620
2019
Q2 		$205K Buy
+892
New +$252K ﹤0.01% 4899

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group's CYCN Position: Q2 2026 in Review

UBS Group reduced its Cyclerion Therapeutics (CYCN) stake by 7.5% in Q2 2026, selling an estimated $831 and leaving 3,135 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8543.

UBS Group first reported a position in CYCN in Q2 2019 and has held it in 26 quarters since. The position peaked at $471K in Q3 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • UBS Group held 3,135 shares of Cyclerion Therapeutics worth $10.6K as of Q2 2026.
  • UBS Group sold 256 Cyclerion Therapeutics shares in Q2 2026, an estimated $831.
  • Cyclerion Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8543 holding.
  • UBS Group first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • UBS Group's Cyclerion Therapeutics position peaked at $471K in Q3 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.